In Vivo RNAi Screening for Pancreatic Cancer Drivers: PILOTing the WDR5-MYC Axis.

Abstract:

:Pancreatic ductal adenocarcinoma (PDAC) represents a major global health problem that causes over 200000 deaths each year worldwide. The disease is highly resistant to cytotoxic and targeted therapies and the average survival is less than 12 months. This situation prompted Alessandro Carugo and Giulio Draetta to develop a novel genetic mouse system, termed Patient-Based In Vivo Lethality to Optimize Treatment (PILOT), to perform functional RNAi-based in vivo screens to uncover and target PDAC drivers. In a forward genetic screen focused on epigenetic modifiers, a WDR5-Myc axis that regulates the DNA replication checkpoint was identified and exploited in vivo for therapeutic intervention.

journal_name

Trends Cancer

journal_title

Trends in cancer

authors

Schneider G,Saur D

doi

10.1016/j.trecan.2016.07.002

subject

Has Abstract

pub_date

2016-08-01 00:00:00

pages

391-392

issue

8

eissn

2405-8033

issn

2405-8025

pii

S2405-8033(16)30081-4

journal_volume

2

pub_type

评论,杂志文章
  • Translin-Trax: Considerations for Oncological Therapeutic Targeting.

    abstract::Dicer-deficient cancers have poor prognoses, which is linked to the degradation of tumour-suppressing miRNA precursors by the Translin-Trax (Tn-Tx) ribonuclease. Inhibition of Tn-Tx potentially offers a new therapeutic intervention point. However, Tn-Tx functions in an array of biological processes, and here we consid...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.02.014

    authors: McFarlane RJ,Wakeman JA

    更新日期:2020-06-01 00:00:00

  • Nutrient Exploitation within the Tumor-Stroma Metabolic Crosstalk.

    abstract::The tumor microenvironment has an essential role in defining tumor malignancy, since it can either promote or prevent tumor initiation and subsequent progression and metastatic dissemination. Recent studies demonstrate that highly aggressive cancer cells display a high degree of metabolic plasticity paralleled by the ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2016.11.001

    authors: Morandi A,Giannoni E,Chiarugi P

    更新日期:2016-12-01 00:00:00

  • PML Nuclear Body Biogenesis, Carcinogenesis, and Targeted Therapy.

    abstract::Targeted therapy has become increasingly important in cancer therapy. For example, targeting the promyelocytic leukemia PML protein in leukemia has proved to be an effective treatment. PML is the core component of super-assembled structures called PML nuclear bodies (NBs). Although this nuclear megaDalton complex was ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.05.005

    authors: Li Y,Ma X,Wu W,Chen Z,Meng G

    更新日期:2020-10-01 00:00:00

  • Connecting Timescales in Biology: Can Early Dynamical Measurements Predict Long-Term Outcomes?

    abstract::Prediction of long-term outcomes from short-term measurements remains a fundamental challenge. Quantitative assessment of signaling dynamics, and the resulting transcriptomic and proteomic responses, has yielded fundamental insights into cellular outcomes. However, the utility of these measurements is limited by their...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.12.008

    authors: Tsabar M,Lovitch SB,Jambhekar A,Lahav G

    更新日期:2021-01-12 00:00:00

  • Plastic Heterogeneity of Innate Lymphoid Cells in Cancer.

    abstract::Innate lymphoid cells (ILCs) fulfill important protective and reparative functions, and have thus been implicated in the maintenance of tissue homeostasis. Dysregulation of their activation is associated with several autoimmune and inflammatory diseases. The current literature on the role of ILCs in cancer is limited ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.03.008

    authors: Wagner M,Moro K,Koyasu S

    更新日期:2017-05-01 00:00:00

  • The Opposing Roles of PIK3R1/p85α and PIK3R2/p85β in Cancer.

    abstract::Dysregulation of the PI3K/PTEN pathway is a frequent event in cancer, and PIK3CA and PTEN are the most commonly mutated genes after TP53. PIK3R1 is the predominant regulatory isoform of PI3K. PIK3R2 is an ubiquitous isoform that has been so far overlooked, but data from The Cancer Genome Atlas shows that increased exp...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.02.009

    authors: Vallejo-Díaz J,Chagoyen M,Olazabal-Morán M,González-García A,Carrera AC

    更新日期:2019-04-01 00:00:00

  • CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer.

    abstract::Cancer-associated fibroblasts (CAFs) are one of the most significant components in the tumour microenvironment (TME), where they can perform several protumourigenic functions. Several studies have recently reported that CAFs are more heterogenous and plastic than was previously thought. As such, there has been a shift...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.09.010

    authors: Pereira BA,Vennin C,Papanicolaou M,Chambers CR,Herrmann D,Morton JP,Cox TR,Timpson P

    更新日期:2019-11-01 00:00:00

  • Advanced Prostate Cancer: Treatment Advances and Future Directions.

    abstract::Prostate cancer affects one in every nine men in the USA and is the second leading cause of cancer-related death. The treatment landscape of advanced prostate cancer is changing rapidly. Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.04.010

    authors: Swami U,McFarland TR,Nussenzveig R,Agarwal N

    更新日期:2020-08-01 00:00:00

  • Liquid Biopsies in Colorectal Cancer: Monitoring Genetic Heterogeneity.

    abstract::Dynamic changes in the colorectal cancer (CRC) signalome and tumor genetic heterogeneity underlie acquired drug resistance. Improving treatment-related decisions is facilitated by an emerging consensus in the classification of tumor subtypes as well as by real-time monitoring of predictive biomarkers in circulating tu...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.01.003

    authors: Gargalionis AN,Papavassiliou AG

    更新日期:2017-03-01 00:00:00

  • Immunotherapeutic Transport Oncophysics: Space, Time, and Immune Activation in Cancer.

    abstract::Immuno-oncology has gained momentum thanks to the success of strategies aimed at enhancing immune-mediated antitumor response. The field of immunotherapeutic transport oncophysics investigates the physical processes that drive cancer immunotherapies. This review discusses three main aspects that determine the outcome ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.11.008

    authors: Nizzero S,Shen H,Ferrari M,Corradetti B

    更新日期:2020-01-01 00:00:00

  • Exons of Leukemia Suppressor Genes: Creative Assembly Required.

    abstract::Alternative splicing (AS) has many important roles in the pathogenesis of leukemia. Recent papers suggest that one of its key aspects is exclusion of 3'-terminal exons in favor of premature termination using intronic polyadenylation signals. This process generates leukemia suppressor isoforms with truncated C termini ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2018.10.005

    authors: Asnani M,Thomas-Tikhonenko A

    更新日期:2018-12-01 00:00:00

  • Lysophosphatidate Signaling: The Tumor Microenvironment's New Nemesis.

    abstract::Lysophosphatidate (LPA) is emerging as a potent mediator of cancer progression in the tumor microenvironment. Strategies for targeting LPA signaling have recently entered clinical trials for fibrosis. These therapies have potential to improve the efficacies of existing chemotherapies and radiotherapy by attenuating ch...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.09.004

    authors: Benesch MGK,Yang Z,Tang X,Meng G,Brindley DN

    更新日期:2017-11-01 00:00:00

  • Targeting Nuclear Receptors for Cancer Therapy: Premises, Promises, and Challenges.

    abstract::Nuclear receptors are a family of transcription factors localized in cell nuclei, sensing specific ligands and fine-tuning a variety of cell physiological events. They have been intensively investigated in cancer biology. With their excellent properties of druggability and actionability, nuclear receptors have demonst...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.11.007

    authors: Yang Z,Gimple RC,Zhou N,Zhao L,Gustafsson JÅ,Zhou S

    更新日期:2020-12-16 00:00:00

  • Challenging Standard-of-Care Paradigms in the Precision Oncology Era.

    abstract::The pace of genomic and immunological breakthroughs in oncology is accelerating, making it likely that large randomized trials will increasingly become outdated before their completion. Traditional clinical research/practice paradigms must adapt to the reality unveiled by genomics, especially the need for customized d...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.12.004

    authors: Subbiah V,Kurzrock R

    更新日期:2018-02-01 00:00:00

  • Microfluidics: A new tool for modeling cancer-immune interactions.

    abstract::In recognition of the enormous potential of immunotherapies against cancer, research into the interactions between tumor and immune cells has accelerated, leading to the recent FDA approval of several drugs that reduce cancer progression. Numerous cellular and molecular interactions have been identified by which immun...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2015.12.003

    authors: Boussommier-Calleja A,Li R,Chen MB,Wong SC,Kamm RD

    更新日期:2016-01-01 00:00:00

  • DUBs, Hypoxia, and Cancer.

    abstract::Alterations in protein ubiquitylation and hypoxia are commonly associated with cancer. Ubiquitylation is carried out by three sequentially acting ubiquitylating enzymes and can be opposed by deubiquitinases (DUBs), which have emerged as promising drug targets. Apart from protein localization and activity, ubiquitylati...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.08.005

    authors: Mennerich D,Kubaichuk K,Kietzmann T

    更新日期:2019-10-01 00:00:00

  • Cirrhosis: A Questioned Risk Factor for Hepatocellular Carcinoma.

    abstract::The liver is one of the major metabolic organs in the body, susceptible to injury caused by various factors. In response to injury, sophisticated mechanisms are engaged to repair and regenerate the damaged liver, preventing its failure. When the damage is chronic, regeneration goes awry, impairing liver function and c...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.08.005

    authors: Garrido A,Djouder N

    更新日期:2021-01-01 00:00:00

  • Protein-Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway.

    abstract::Given the implication of aberrant RAS-extracellular signal-regulated kinase (ERK) signaling in the development of a large number of tumor types, this route is under intense scrutiny to identify new anticancer drugs. Most avenues in that direction have been primarily focused on the inhibition of the catalytic activity ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2018.07.002

    authors: García-Gómez R,Bustelo XR,Crespo P

    更新日期:2018-09-01 00:00:00

  • A Molecular Take on Malignant Rhabdoid Tumors.

    abstract::The molecular basis for the clinical heterogeneity observed in patients with malignant rhabdoid tumors is unknown. Recently, two reports revealed molecular inter-tumor heterogeneity in teratoid/rhabdoid tumors (ATRTs) and extra-cranial MRTs (ecMRTs) using genomic, transcriptomic and epigenomic profiling. Distinct mole...

    journal_title:Trends in cancer

    pub_type: 评论,杂志文章

    doi:10.1016/j.trecan.2016.04.003

    authors: Tang M,Verhaak RG

    更新日期:2016-05-01 00:00:00

  • Repurposing Drugs in Oncology: Next Steps.

    abstract::The repurposing of existing non-cancer drugs is a potential source of new treatment options for cancer patients with high unmet medical needs. While scientific research is progressing rapidly in the field of drug repurposing, the implementation of drug repurposing still faces important financial and regulatory hurdles...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2017.06.007

    authors: Verbaanderd C,Meheus L,Huys I,Pantziarka P

    更新日期:2017-08-01 00:00:00

  • TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.

    abstract::TP53 is the most frequently mutated gene in breast cancer, but its role in survival is confounded by different studies concluding that TP53 mutations are associated with negative, neutral, or positive outcomes. Closer examination showed that many studies were limited by factors such as imprecise methods to detect TP53...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.01.007

    authors: Shahbandi A,Nguyen HD,Jackson JG

    更新日期:2020-02-01 00:00:00

  • Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All.

    abstract::Ibrutinib resistance, as a result of coordinated rewiring of signaling networks and enforced tumor microenvironment (TME)-lymphoma interactions, drives unrestrained proliferation and disease progression. To combat resistance mechanisms, we must identify the compensatory resistance pathways and the central modulators o...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2018.01.004

    authors: Shah B,Zhao X,Silva AS,Shain KH,Tao J

    更新日期:2018-03-01 00:00:00

  • Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?

    abstract::Traditionally, the efficacy of novel cancer therapies has been confirmed in patients failing regular treatment before being tested in early disease. Improved understanding of the mechanisms guiding therapeutic efficacy may challenge this dogma, suggesting novel therapies to move into early evaluation based on biologic...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.11.010

    authors: Lønning PE

    更新日期:2020-12-22 00:00:00

  • Immunity Gone Astray - NETs in Cancer.

    abstract::Neutrophil extracellular traps (NETs) have emerged as significant contributors to cancer-associated pathologies such as metastasis, thrombosis, and organ dysfunction in preclinical models. We review recent discoveries of the involvement of NETs in human cancers and suggest tumor-induced NET formation as an interesting...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2016.10.012

    authors: Cedervall J,Olsson AK

    更新日期:2016-11-01 00:00:00

  • Born to Kill: NK Cells Go to War against Cancer.

    abstract::Preclinical and clinical data emerging over the past year demonstrate that cancer cells suppress the cytotoxic functions of natural killer cells by a variety of mechanisms. These findings reveal a new arsenal of actionable therapeutic targets to drive clinically relevant immune responses against cancer. ...

    journal_title:Trends in cancer

    pub_type: 信件

    doi:10.1016/j.trecan.2018.12.005

    authors: Wennerberg E,Galluzzi L

    更新日期:2019-03-01 00:00:00

  • Redox Debt Leads to Metabolic Bankruptcy in Tumors.

    abstract::Lactate dehydrogenase (LDH) accounts for the fermentative component of aerobic glycolysis, a near ubiquitous metabolic alteration in cancer. Recently, Oshima et al. developed a bioavailable LDH inhibitor that decreases tumor growth in mice and functions synergistically with mitochondrial respiration inhibitors. These ...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.02.012

    authors: Quon E,Hart ML,Sullivan LB

    更新日期:2020-05-01 00:00:00

  • Emerging Roles of GLI-Similar Krüppel-like Zinc Finger Transcription Factors in Leukemia and Other Cancers.

    abstract::GLI-similar 1-3 (GLIS1-3), a subfamily of Krüppel-like zinc finger transcription factors, function as key regulators of several biological processes important to oncogenesis, including control of cell proliferation, differentiation, self-renewal, and epithelial-mesenchymal transition. This review provides a short over...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.07.005

    authors: Jetten AM

    更新日期:2019-09-01 00:00:00

  • Cancer of Unknown Primary in the Molecular Era.

    abstract::Cancer of unknown primary (CUP) is a rare malignancy that presents with metastatic disease and no identifiable site of origin. Most patients have unfavorable features and attempts to treat based on tissue-of-origin identification have not yielded a survival advantage compared with empiric chemotherapy. Next-generation...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.11.002

    authors: Kato S,Alsafar A,Walavalkar V,Hainsworth J,Kurzrock R

    更新日期:2021-01-27 00:00:00

  • Prolonging Reproductive Life after Cancer: The Need for Fertoprotective Therapies.

    abstract::The survival rate of reproductive-age patients with cancer is increasing, reflecting the advent of better and more efficient therapies. Cancer survivors seek the resumption of a normal and healthy life, which often includes starting a family. Unfortunately, many cancer treatments increase the risk of premature ovarian...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2016.03.006

    authors: Woodard TL,Bolcun-Filas E

    更新日期:2016-05-01 00:00:00

  • Cadherins Glycans in Cancer: Sweet Players in a Bitter Process.

    abstract::Cadherins are key components in tissue morphogenesis and architecture, contributing to the establishment of cohesive cell adhesion. Reduced cellular adhesiveness as a result of cadherin dysfunction is a defining feature of cancer. During tumor development and progression, major changes in the glycan repertoire of canc...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2016.08.003

    authors: Carvalho S,Reis CA,Pinho SS

    更新日期:2016-09-01 00:00:00